{"podcast":{"title":"HCPLive Podcasts","slug":"hcplive-podcasts-19526","podcast_index_feed_id":19526,"rss_url":"https://audioboom.com/channels/5004077.rss","website_url":"https://audioboom.com/channels/5004077","image_url":"https://audioboom.com/i/40144427.png","author":"HCPLive.com","episode_count":243,"summary":"Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.","last_synced_at":null,"page_url":"https://stenobird.com/podcast/hcplive-podcasts-19526"},"episode":{"title":"Liver Lineup: Advances, Gaps, and What’s Next in Viral Hepatitis","slug":"liver-lineup-advances-gaps-and-what-s-next-in-viral-hepatitis","published_at":"2026-02-04T14:38:33+00:00","page_url":"https://stenobird.com/podcast/hcplive-podcasts-19526/liver-lineup-advances-gaps-and-what-s-next-in-viral-hepatitis","show_page_url":"https://stenobird.com/podcast/hcplive-podcasts-19526","url":"https://audioboom.com/posts/8856848","audio_url":"https://audioboom.com/posts/8856848.mp3?modified=1770215985&sid=5004077&source=rss","summary":"In this episode of Liver Lineup: Updates and Unfiltered Insights , hosts Nancy Reau, MD, and Kimberly Brown, MD, tackle a paradox that continues to define viral hepatitis care: despite curative therapies for hepatitis C and highly effective suppression for hepatitis B, global and domestic elimination goals remain out of reach. The conversation reframes viral hepatitis not as a “finished” chapter in hepatology, but as an ongoing public health challenge shaped by missed screening, gaps in linkage to care, and uneven adoption of evidence-based interventions. Key episode timestamps: 0:00:00 – Hepatitis elimination gaps; dialysis-unit success; primary-care screening barriers. 0:04:30 – Statins in HBV/HCV: reduced HCC/decompensation; safety in compensated disease. 0:08:41 – GLP‑1 agonists: improved liver outcomes and cancer/cardiometabolic profile; safety concerns addressed. 0:13:21 – HBV functional cure and Bepi: niche role, durability, small but meaningful responder group. 0:19:28 – HBV/HDV: disease severity; new mAb + siRNA regimen; comparison with existing options; access issues. 0:23:28 – Bulevirtide durability data; real‑world compassionate-use case with recompensation and early HCC.","meta_description":"In this episode of Liver Lineup: Updates and Unfiltered Insights , hosts Nancy Reau, MD, and Kimberly Brown, MD, tackle a paradox that continues to define…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1732,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/hcplive-podcasts-19526/episodes/liver-lineup-advances-gaps-and-what-s-next-in-viral-hepatitis/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/hcplive-podcasts-19526/liver-lineup-advances-gaps-and-what-s-next-in-viral-hepatitis.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}